By Eric Suhler, MD
    Subspecialty Day 2012: Uveitis

    In this presentation from the 2012 Annual Meeting, Dr. Eric Suhler discusses evolving systemic therapy for uveitis including:

    • Open-label studies including abatacept, tocilizumab, rituximab, and TNF blockers
    • LX211 (voclosporin) and the Lux Uveitis Multicenter Investigation of a New Approach to Treatment (LUMINATE) studies
    • Visual I, II, and III clinical trials
    • Secukinumab studies
    • IL-1 blockers